The Latest Advances in Phage Display Technology
Despite advances that include chimeric antibodies and transgenic mice, in vivo antibody production still poses many technical, financial, and ethical challenges to producing biotherapeutics. Addressing these challenges is critical, as antibodies represent an increasing fraction of therapeutics receiving FDA approval.
Read this article to learn:
- The immunogenicity, efficacy, contamination, and animal welfare issues associated with traditional in vivo antibody production approaches
- The diversity, speed, and precise control over antibody production that can be acheived with phage display
- Why other alternatives, such as transgenic mice and isolating antibodies directly from patients, are best for only very specific applications
Download the Article
Share a little information with us to access the entire article now.
Thank you for your interest!
Your download is ready.Download PDF
What to Consider When Choosing a Library for Drug Discovery
Learn the key differences between library formats (immune, naïve, synthetic, and semi-synthetic) and find out the best source for your next discovery project.
Overcome the Challenges of PK Assay Development Using Custom Antibodies
Learn how the generation of anti-idiotypic antibodies and other high specificity tool antibody critical reagents are made to support PK assay design.